Stella Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	323	961	269	229	100
Revenue Growth (YoY)	-66.39%	257.25%	17.47%	129.00%	-51.22%
Cost of Revenue	44	116	52	22	15
Gross Profit	279	845	217	207	85
Selling, General & Admin	1,028	590	571	625	555
Research & Development	-	328	393	374	255
Operating Expenses	1,028	935	977	1,013	826
Operating Income	-749	-90	-760	-806	-741
Interest Expense	-7	-4	-2	-2	-3
Interest & Investment Income	-	1	1	1	-
Other Non Operating Income (Expenses)	-22	-45	-	31	-20
Pretax Income	-778	-138	-761	-776	-764
Income Tax Expense	2	2	2	2	3
Net Income	-780	-140	-763	-778	-767
Net Income to Common	-780	-140	-763	-778	-767
Shares Outstanding (Basic)	34	33	31	29	28
Shares Outstanding (Diluted)	34	33	31	29	28
Shares Change (YoY)	1.93%	7.76%	7.27%	2.83%	40.17%
EPS (Basic)	-22.93	-4.19	-24.63	-26.94	-27.31
EPS (Diluted)	-22.93	-4.19	-24.63	-26.94	-27.31
Free Cash Flow	-345	136	-886	-853	-1,127
Free Cash Flow Per Share	-10.14	4.07	-28.60	-29.54	-40.13
Gross Margin	86.38%	87.93%	80.67%	90.39%	85.00%
Operating Margin	-231.89%	-9.37%	-282.53%	-351.96%	-741.00%
Profit Margin	-241.49%	-14.57%	-283.64%	-339.74%	-767.00%
Free Cash Flow Margin	-106.81%	14.15%	-329.37%	-372.49%	-1127.00%
EBITDA	-721	-56	-725	-771	-707
EBITDA Margin	-223.22%	-5.83%	-269.52%	-	-
D&A For EBITDA	28	34	35	35	34
EBIT	-749	-90	-760	-806	-741
EBIT Margin	-231.89%	-9.37%	-282.53%	-	-